LALPATHLAB2021-07-012021-09-30in-bse-fin:OneOperatingExpenses01Member LALPATHLAB2021-07-012021-09-30in-bse-fin:OneOperatingExpenses02Member LALPATHLAB2021-07-012021-09-30in-bse-fin:FourOperatingExpenses01Member LALPATHLAB2021-07-012021-09-30in-bse-fin:FourOperatingExpenses02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares LALPATHLAB 2021-04-01 2022-03-31 2021-10-19 INR Millions Half yearly true Cash Flow Indirect Single segment The business of running laboratories for carrying out Pathological investigations of various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations. 2021-07-01 2021-09-30 Unaudited Standalone 4704000000.00 153000000.00 4857000000.00 1179000000.00 0.00 0.00 781000000.00 43000000.00 181000000.00 1414000000.00 3598000000.00 1259000000.00 0.00 1259000000.00 326000000.00 -6000000.00 320000000.00 0.00 939000000.00 0.00 0.00 0.00 0.00 939000000.00 -20000000.00 919000000.00 0.00 0.00 833000000.00 10 11.36 11.31 0.00 0.00 11.36 11.31 i. The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 26 October, 2021. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter and six months ended 30 September, 2021 and they have expressed an unmodified conclusion on the aforesaid results. ii. These financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. iii. During the six months ended 30 September, 2021, the Company has made a further investment of INR 45 million in its wholly owned subsidiary, PathLabs Unifiers Private Limited, through subscription of additional equity shares. iv. Subsquent to the quarter and six months ended 30 September, 2021 the Company has made a further investment of INR 1 million (KES 1.48 million) in its wholly owned subsidiary, Dr. Lal PathLabs Kenya Private Limited, through subscription of additional equity shares. v. The results of the current quarter and six months ended 30 September 2021, are not strictly comparable with the results of quarter ended 30 June, 2021, quarter and six months ended 30 September, 2020 due to resurgent wave of COVID-19 in quarter ended 30 June, 2021 and nationwide lockdown in the corresponding previous six month period. vi. The Board of Directors in their meeting held on 3 February, 2020 had approved the Scheme of Amalgamation of APL Institute of Clinical Laboratory & Research Private Limiter (APL) with the Company w.e.f. 1 April, 2020 (the appointed date). As per the said scheme, the undertaking of APL shall stand transferred to and vested in the Company on a going concern basis without any further act, deed of matter. The scheme of amalgamation is subject to approval by the National Company Law Tribunal and other statutory approvals. vii. The Board of Directors of the Company had approved the first interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 30 July, 2021 which has been paid during the quarter ended September 30, 2021. viii. The Board of Directors of the Company, which has been identified as being the chief operating decision maker (CODM), evaluates the Company's performance, allocates resources based on the analysis of the various performance indicators of the Company as a single unit. Therefore there is no reportable segment for the Company, in accordance with the requirements of Indian Accounting Standard 108- 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015. ix. The Indian Parliament has approved the Code on Social Security, 2020 ('the Code') which, inter alia, deals with employee benefits during employment and post-employment. The Code has been published in the Gazette of India. The effective date of the Code is yet to be notified. In view of this, the Company is in the process of assessing the impact of the relevant provisions. x. Refer Annexure A for Statement of standalone Assets and Liabilities. Single segment 2021-04-01 2021-09-30 Unaudited Standalone 10353000000.00 288000000.00 10641000000.00 2516000000.00 0.00 0.00 1589000000.00 87000000.00 349000000.00 3189000000.00 7730000000.00 2911000000.00 0.00 2911000000.00 816000000.00 -77000000.00 739000000.00 0.00 2172000000.00 0.00 0.00 0.00 0.00 2172000000.00 -21000000.00 2151000000.00 0.00 0.00 833000000.00 10 26.28 26.18 0.00 0.00 26.28 26.18 Fees to collection centers/channel partners 685000000.00 Other Expenses 729000000.00 Fees to collection centers/channel partners 1585000000.00 Other Expenses 1604000000.00 87000000.00 -101000000.00 -24000000.00 0.00 -95000000.00 0.00 -15000000.00 0.00 0.00 256000000.00 0.00 39000000.00 0.00 349000000.00 0.00 64000000.00 0.00 19000000.00 0.00 0.00 16000000.00 256000000.00 177000000.00 -13000000.00 0.00 0.00 0.00 -22000000.00 0.00 449000000.00 3360000000.00 0.00 0.00 0.00 539000000.00 0.00 2821000000.00 0.00 45000000.00 1445000000.00 2116000000.00 0.00 0.00 0.00 0.00 0.00 307000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 14000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 16000000.00 263000000.00 0.00 -588000000.00 0.00 -1346000000.00 0.00 0.00 0.00 0.00 0.00 0.00 1000000.00 0.00 0.00 0.00 0.00 122000000.00 1157000000.00 88000000.00 0.00 0.00 -1366000000.00 109000000.00 0.00 109000000.00 2317000000.00 2426000000.00